Why the study?
Does liver-specific inhibition of ChREBP improve hepatic steatosis and insulin resistance in ob/ob mice?
Population
Leptin-deficient (ob/ob) mice
Design
Preclinical
Follow-up
7 days
Authors
Loading...
Preclinical only; leaves open whether ChREBP inhibition benefits patients with steatosis or insulin resistance.
Does liver-specific inhibition of ChREBP improve hepatic steatosis and insulin resistance in ob/ob mice?
Liver-specific inhibition of ChREBP improves hepatic steatosis and restores insulin sensitivity in a mouse model of obesity, highlighting its role in metabolic regulation.
Dentin et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: